ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Australia venture teams with Fujifilm for stem cell therapy

Cynata to run trials in Japan and US for transplant patients

Cynata Therapeutics' stem-cell-based treatment can help leukemia patients fight complications from bone marrow transplants.   © Reuters

TOKYO -- Cynata Therapeutics will start clinical trials in Japan and the U.S. on a stem-cell-based treatment for transplant patients under a licensing agreement with Fujifilm Holdings, the Australian medical venture's CEO said Friday.

The agreement with Fujifilm, which holds a 10%-plus stake in Cynata, will be signed this fiscal year, with clinical trials to enter their second phase in fiscal 2019, Ross Macdonald told reporters.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more